CureVac Secures Patent Win Against BioNTech

CureVac has received a favorable ruling from the European Patent Office regarding its patent EP 3 708 668 B1. BioNTech's challenge, raised in April 2023, was largely dismissed. The patent, concerning a pioneering mRNA technology, remains valid in amended form. A hearing on potential infringement by BioNTech is set for July 1, 2025, in Düsseldorf, Germany.

This decision is significant in the broader legal battle between CureVac and BioNTech, involving six intellectual property rights. CureVac's CEO, Dr. Alexander Zehnder, highlighted the importance of this decision for recognizing the company's contribution to mRNA-based COVID-19 vaccines and its ongoing efforts to expand mRNA medicine.

EP 3 708 668 B1 pertains to a technique enhancing the efficacy of mRNA constructs, crucial for developing transformative medicines. CureVac remains represented by leading law firms in Germany and the U.S.